STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease

STAT PlusBiotech Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease The successful study outcome could significantly boost the drug’s sales if it’s cleared by regulators Manage alerts for this article Email this article Share this article By Adam FeuersteinMay 5, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Cytokinetics said Tuesday that its drug Myqorzo significantly improved heart failure symptoms and cardiovascular fitness in patients with non-obstructive hypertrophic cardiomyopathy, an inherited heart disorder. The results, reported in a company press release, achieved the dual efficacy goals of a Phase 3 clinical trial, called ACACIA, with statistical significance.Advertisement Cytokinetics is in the early days of Myqorzo’s commercial launch as a treatment for the more severe “obstructive” form of hypertrophic cardiomyopathy, or HCM. The successful outcome of the ACACIA study, if also cleared by regulators, could greatly expand the number of HCM patients eligible for treatment — and boost the drug’s peak sales to $5 billion annually, according to analyst forecasts. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, cardiology, drug development, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Biotech May 5, 2026 STAT Plus: Johnson & Johnson advances IBD therapy, despite trial miss The Readout May 4, 2026 UCB to acquire maker of antibody treatments for autoimmune diseases Advertisement Exclusive May 4, 2026 STAT Plus: Biotech raises $42 million to run Huntington’s disease trial The Readout May 1, 2026 STAT Plus: Axsome wins FDA nod for Alzheimer’s agitation Biotech May 1, 2026 STAT Plus: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more Subscriber Picks